Triple

T23417460
Position Surface form Disambiguated ID Type / Status
Subject Bristol Myers Squibb E560549 entity
Predicate product P490 FINISHED
Object Breyanzi NE NERFINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Breyanzi | Statement: [Bristol Myers Squibb, product, Breyanzi]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Breyanzi
Context triple: [Bristol Myers Squibb, product, Breyanzi]
  • A. Beutler
    Beutler is a surname most notably associated with Bruce A. Beutler, an American immunologist and Nobel Prize laureate recognized for his work on innate immunity.
  • B. Trikafta
    Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
  • C. Ultomiris
    Ultomiris is a long-acting monoclonal antibody therapy used to treat rare complement-mediated blood disorders such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
  • D. Onpattro
    Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
  • E. Bantigen
    Bantigen is a small locality within the municipality of Bolligen in the canton of Bern, Switzerland.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Breyanzi
Target entity description: Breyanzi is a CD19-directed CAR T-cell therapy used to treat certain types of relapsed or refractory large B-cell lymphoma.
  • A. Beutler
    Beutler is a surname most notably associated with Bruce A. Beutler, an American immunologist and Nobel Prize laureate recognized for his work on innate immunity.
  • B. Trikafta
    Trikafta is a breakthrough combination therapy for cystic fibrosis that targets the underlying genetic defect to improve lung function and reduce symptoms in eligible patients.
  • C. Ultomiris
    Ultomiris is a long-acting monoclonal antibody therapy used to treat rare complement-mediated blood disorders such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
  • D. Onpattro
    Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
  • E. Bantigen
    Bantigen is a small locality within the municipality of Bolligen in the canton of Bern, Switzerland.
  • F. None of above. chosen

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2454cb1108190ab21ada5411a7146 completed April 17, 2026, 2:35 p.m.
NER Named-entity recognition batch_69f1a516d158819081e9710b4e372a21 completed April 29, 2026, 6:28 a.m.
Created at: April 17, 2026, 5:39 p.m.